Literature DB >> 8822501

Mechanisms of action of endocrine treatment in breast cancer.

E Lønning1, E A Lien.   

Abstract

Endocrine treatment plays an important role in the therapy of breast cancer. While the basic mechanisms are understood, additional mechanisms may be of importance to their action and they may also contribute to the mechanism(s) of acquired resistance. Currently, several novel drugs are entering into clinical trials. Observations of the absence or presence of cross resistance to novel 'pure' steroidal antiestrogens and the non-steroidal tamoxifen may add important information to our understanding of the mechanisms of action of both classes of drugs. Similarly, exploration of different aromatase inhibitors in sequence or concert, as well as the combining of different endocrine treatment options may be warranted. Additionally, alterations in different biochemical parameters such as growth factors should not only be carefully explored in relation to treatment options but should also be followed during the course of treatment to asess alterations over time and in relation to the development of drug resistance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8822501     DOI: 10.1016/1040-8428(94)00172-3

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  7 in total

Review 1.  Clinical pharmacokinetics of aromatase inhibitors and inactivators.

Authors:  Per Lønning
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Molecular basis for therapy resistance.

Authors:  Per E Lønning
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

Review 3.  Tamoxifen and secondary tumours. An update.

Authors:  N Wilking; E Isaksson; E von Schoultz
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

Review 4.  Is there a growing role for endocrine therapy in the treatment of breast cancer?

Authors:  P E Lønning
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

5.  Tamoxifen and megestrol acetate for postmenopausal breast cancer: diverging effects on liver proteins, androgens, and glucocorticoids.

Authors:  L Löfgren; B Wallberg; N Wilking; T Fornander; L E Rutqvist; K Carlström; B von Schoultz; E von Schoultz
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

Review 6.  Premenopausal breast cancer: chemotherapy and endocrine therapy.

Authors:  Herbert G Sayer; Roland Kath; Kay-Oliver Kliche; Klaus Höffken
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 7.  IGF binding proteins (IGFBPs) and regulation of breast cancer biology.

Authors:  Claire M Perks; Jeff M P Holly
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-25       Impact factor: 2.673

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.